Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

61.13
Delayed Data
As of Dec 02
 +0.37 / +0.61%
Today’s Change
47.97
Today|||52-Week Range
65.46
+15.73%
Year-to-Date
Why Bristol-Myers Squibb Co. Stock Surged in November
Dec 03 / MotleyFool.com - Paid Partner Content
Novo Nordisk: shot in the dark
Nov 25 / FT.com - Paid Partner Content
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
Dec 02 / Zacks.com - Paid Partner Content
Merck's New Drugs, Cost Management to Fuel Growth in 2017
Nov 25 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytr...
Dec 02 / Zacks.com - Paid Partner Content
Better Buy: Celgene Corporation vs. Merck & Co.
Nov 25 / MotleyFool.com - Paid Partner Content
Alexandria Real Estate, Merck Ink Long-Term Pharma Lease
Dec 01 / Zacks.com - Paid Partner Content
Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
Nov 25 / Zacks.com - Paid Partner Content
5 Top Performing S&P 500 Stocks of November
Dec 01 / Zacks.com - Paid Partner Content
Merck (MRK) Announces 2.2% Increase in Quarterly Dividend
Nov 24 / Zacks.com - Paid Partner Content
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
Dec 01 / Zacks.com - Paid Partner Content
Top Research Reports for General Dynamics, DuPont, & Merck
Nov 23 / Zacks.com - Paid Partner Content
3 Ways Organovo Holdings, Inc. Plans to Grow Exponentially for Years to Come
Dec 01 / MotleyFool.com - Paid Partner Content
AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials
Nov 23 / Zacks.com - Paid Partner Content
Quest to cure Alzheimer's disease exhibits symptoms of failure
Nov 30 / FT.com - Paid Partner Content
AstraZeneca given green light to resume cancer drug trials
Nov 22 / FT.com - Paid Partner Content
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
Nov 30 / Zacks.com - Paid Partner Content
Stunning! Dow hits new high of 19,000 as Trump rally continues
Nov 22 / CNNMoney.com
Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
Nov 30 / Zacks.com - Paid Partner Content
Stock Market News for November 21, 2016
Nov 21 / Zacks.com - Paid Partner Content
Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Mine Field
Nov 30 / TheStreet.com - Paid Partner Content
$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Mark...
Nov 21 / MotleyFool.com - Paid Partner Content
Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Hand...
Nov 29 / TheStreet.com - Paid Partner Content
The Trump market rally: Too far, too fast
Nov 14 / CNNMoney.com
Big Pharma healthcare R&D steps out into the open
Nov 29 / FT.com - Paid Partner Content
Clinton defeat provides antidote to US drugmakers
Nov 10 / FT.com - Paid Partner Content
Merck: Keytruda's Priority Review for New Cancer Indication
Nov 29 / Zacks.com - Paid Partner Content
Wall Street rallies led by healthcare and banks
Nov 09 / FT.com - Paid Partner Content
Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALI...
Nov 28 / Zacks.com - Paid Partner Content
Drug and biotech stocks soar on Trump victory
Nov 09 / CNNMoney.com
J&J (JNJ) Confirms it Approached Actelion for Possible Deal
Nov 28 / Zacks.com - Paid Partner Content